Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

Lluís Puig Sanz, Lluís Rusiñol

Producció científica: Contribució a una revistaArticle de revisióRecercaAvaluat per experts

16 Cites (Scopus)


The Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways mediate the intracellular signaling of cytokines in a wide spectrum of cellular processes. They participate in physiologic and inflammatory cascades and have become a major focus of research, yielding novel therapies for immune-mediated inflammatory diseases (IMID). Genetic linkage has related dysfunction of Tyrosine kinase 2 (Tyk2)-the first member of the Jak family that was described-to protection from psoriasis. Furthermore, Tyk2 dysfunction has been related to IMID prevention, without increasing the risk of serious infections; thus, Tyk2 inhibition has been established as a promising therapeutic target, with multiple Tyk2 inhibitors under development. Most of them are orthosteric inhibitors, impeding adenosine triphosphate (ATP) binding to the JH1 catalytic domain-which is highly conserved across tyrosine kinases-and are not completely selective. Deucravacitinib is an allosteric inhibitor that binds to the pseudokinase JH2 (regulatory) domain of Tyk2; this unique mechanism determines greater selectivity and a reduced risk of adverse events. In September 2022, deucravacitinib became the first Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis. A bright future can be expected for Tyk2 inhibitors, with newer drugs and more indications to come.
Idioma originalEnglish
Número d’article3391
RevistaInternational Journal of Molecular Sciences
Estat de la publicacióPublicada - de febr. 2023


Navegar pels temes de recerca de 'Tyk2 Targeting in Immune-Mediated Inflammatory Diseases'. Junts formen un fingerprint únic.

Com citar-ho